Liver Receptor Homolog 1 Is a Negative Regulator of the Hepatic Acute-Phase Response

Nicolas Venteclef,1 Jason C. Smith,2 Bryan Goodwin,3 and Philippe Delerive1*

GlaxoSmithKline, Cardiovascular & Urogenital Center of Excellence for Drug Discovery, 25 Avenue du Quebec, 91951 Les Ulis, France; GlaxoSmithKline, Laboratory Animal Sciences, The Frythe, United Kingdom; and GlaxoSmithKline, High Throughput Biology, Research Triangle Park, North Carolina 27709

Received 3 April 2006/Returned for modification 26 April 2006/Accepted 29 June 2006

The orphan nuclear receptor liver receptor homolog 1 (LRH-1) has been reported to play an important role in bile acid biosynthesis and reverse cholesterol transport. Here, we show that LRH-1 is a key player in the control of the hepatic acute-phase response. Ectopic expression of LRH-1 with adenovirus resulted in strong inhibition of both interleukin-6 (IL-6)- and IL-1β-stimulated haptoglobin, serum amyloid A, and fibrinogen β gene expression in hepatocytes. Furthermore, induction of the hepatic inflammatory response was significantly exacerbated in HepG2 cells expressing short hairpin RNA targeting LRH-1 expression. Moreover, transient-transfection experiments and electrophoretic mobility shift and chromatin immunoprecipitation assays revealed that LRH-1 regulates this cytokine-elicited inflammatory response by, at least in part, antagonizing the CCAAT/enhancer binding protein β signaling pathway. Finally, we show, by using LRH-1 heterozygous mice, that LRH-1 is involved in the control of the inflammatory response at the hepatic level in vivo. Taken together, our results outline an unexpected role for LRH-1 in the modulation of the hepatic acute-phase response.

Nuclear receptors (NRs) are ligand-activated transcription factors which have central roles in nearly every aspect of development and adult physiology (22, 34). NRs have been shown to be key players in the control of the inflammatory response (53). Among them, peroxisome proliferator-activated receptors (PPAR) and liver X receptors (LXR) have been reported to be molecular links between lipid metabolism and the inflammatory response (10, 27). They exert their anti-inflammatory activities in various tissues, including the liver and macrophages, by antagonizing cytokine-mediated gene expression via transcriptional cross talk with NF-κB, AP-1, CCAAT/enhancer binding protein (C/EBP), and signal transducers and activators of transcription (STAT) signaling pathways (12, 23). The liver is the primary site of the acute-phase response (APR), which is the host reaction in response to trauma, infection, tissue damage, or acute inflammation (3). This APR plays an important role in limiting tissue injury and the innate immune response. A major component of this APR is the altered hepatic synthesis of a wide spectrum of proteins involved in coagulation, lipid metabolism, and the complement system (20). Cytokines, more specifically, interleukin-6 (IL-6) and IL-1β, are the physiological mediators of this APR. They are mainly produced by monocytes and macrophages at inflammatory sites. This cytokine-induced APR is characterized by changes in the concentrations of plasma proteins known as acute-phase proteins (APPs) that are largely produced by hepatocytes. These may be positive APPs (up-regulated) or negative APPs (down-regulated). Negative APPs include carrier proteins such as albumin, whereas positive APPs play a direct role in the inflammatory process (5, 20). C-reactive protein (CRP), serum amyloid A (SAA), fibrinogen β (FGB), haptoglobin (HP), and plasminogen activator inhibitor 1 (PAI-1, SERPINE1) are the best defined. APPs have been divided into two major classes according to their responsiveness to cytokines; class I APPs are responsive to IL-1β and other cytokines, whereas class II APPs are solely responsive to IL-6 and related cytokines. APP expression is regulated at the transcriptional level by three important transcription factors, NF-κB, STAT3, and C/EBPs. Chronic changes in the levels of these APPs are considered to be detrimental rather than beneficial to the host. Interestingly, many APPs are well-characterized markers of chronic inflammatory diseases such as atherosclerosis (8). Among them, CRP has been shown in certain studies to be a more powerful predictor of cardiovascular risk than traditional risk factors such as low-density lipoprotein (LDL). Indeed, CRP levels predict cardiovascular risk independently of LDL or high-density lipidoprotein (HDL) cholesterol levels (47).

The orphan NR liver receptor homolog 1 (LRH-1; NR5A2) is the mammalian homolog of the Drosophila fushi tarazu factor 1 (FTZ-F1) receptor (FTZ-F1; NR5A3) and, like FTZ-F1, binds its cognate target sequence (5′-[Py]CAAGG[Py][C][Pu]-3′) as a monomer (21). It is highly expressed in the liver, intestine, ovary, and pancreas (21, 48). Recently, several groups reported independently the crystal structure of the LRH-1 ligand-binding domain and identified phospholipids buried in the hydrophobic cavity, raising the possibility that phospholipids are natural ligands for LRH-1 (30, 32, 39, 54). LRH-1 plays an important role in the embryonic development via the regulation of key transcription factors such as Oct4 and hepatic nuclear factors HNF-3β, HNF-4α, and HNF-1α (25, 40). Recently, LRH-1 was shown to regulate expression of aromatase (CYP19) in ovarian and adipose tissues (11, 40) and adiponectin in adipocytes (26). Furthermore, LRH-1 has recently been reported to be involved in intestinal crypt cell renewal by coactivating β-catenin on the cyclin D1 promoter (6). In addition, LRH-1 is...
believed to be a key player in cholesterol homeostasis (15). LRH-1 has been shown to play a pivotal role in the transcriptional regulation of CYP7A1, the rate-limiting enzyme of the bile acid biosynthetic pathway (37), and CYP8B1, the oxysterol 12α-hydroxylase required for cholic acid production (7). Moreover, LRH-1 has been reported to regulate expression of APO AI (13), ABCG5/ABCG8 (18), CETP (35), SR-BI (48), and the carboxyl ester lipase (16), thereby implicating this receptor in HDL remodeling and cholesterol transport.

Since NRs have been shown to be at the crossroads between lipid metabolism and the inflammatory response, we investigated the potential involvement of LRH-1 in the hepatic APR. Overexpression studies and gene-silencing experiments indicate that LRH-1 modulates the cytokine-stimulated APR in vitro but also in vivo, outlining an unexpected role for LRH-1 in hepatic inflammation control.

MATERIALS AND METHODS

Cell culture. HepG2 cells (American Type Culture Collection, Manassas, VA) were maintained in basic Eagle’s medium supplemented with 2 mM glutamine, 1% nonessential amino acids, and 10% (vol/vol) fetal calf serum (FCS) in an atmosphere of 5% CO₂ at 37°C. Cynomolgus primary hepatocytes were provided by Biopredic (Rennes, France) and cultured in William’s E medium supplemented with 1% FCS, 10 nM dexamethasone, 100 U/ml penicillin, 100 μg/ml streptomycin, and insulin-transferrin-selenium G.

Plasmids. Plasmid pSG5-LRH-1 has been previously described (13). Plasmid pSG5 was purchased from Stratagene (La Jolla, CA). The pCEBP, pNF-κB, and pSTAT3 reporter vectors were provided by Panomics. The human HP promoter construct (~460 to +5) was obtained by PCR amplification with human genomic DNA as the template. The resulting PCR product was inserted as a KpnI/HindIII fragment into the pGL3 basic vector (Promega), yielding HP-Luc. The mutation of the C/EBP binding site within the human HP promoter was obtained by site-directed mutagenesis (Stratagene, La Jolla, CA) with the oligonucleotides 5’-CAAGTGTGAAGCGATATCCTCAACTCTTAACAG-3’ and 5’-CTGTTAAGAGTTGAGGATATCGCTTCACACTTG-3’. All constructs were verified by DNA sequence analysis.

Transient-transfection assays. HepG2 cells, plated in 24-well plates at 50 to 60% confluency in basic Eagle’s medium supplemented with 10% FCS, were transiently transfected with reporter and receptor expression plasmids with FuGene 6 reagent (Roche Molecular Biochemical, Indianapolis, IN) as indicated in the figure legends. The pSEAP2 expression plasmid (Clontech) was cotransfected to assess transfection efficiency. At 48 h posttransfection, cells were collected and assayed for luciferase and alkaline phosphatase activities. All experiments were repeated at least three times.

Stable cell line generation. HepG2 cells stably expressing short hairpin RNA (shRNA) targeting LRH-1 expression or LacZ as a control were engineered with the BLOCK-it inducible H1 RNA interference entry vector kit (Invitrogen, Carlsbad, CA). Briefly, 50-nucleotide DNA oligonucleotides encoding the shRNA targeting human LRH-1 or LacZ were ligated into the pENTR/H1/T0 vector, yielding pshLRH-1 and pshLacZ, respectively. The sequence targeting LRH-1 (GenBank accession number AB019246) corresponds to the coding region (nucleotides 1438 to 1458) relative to the first nucleotide of the start codon. HepG2 cells (40% confluence) were then transfected with pshLRH-1 and pshLacZ as indicated in the figure legends. The pSEAP2 reporter plasmid (Clontech) was cotransfected to assess transfection efficiency. At 24 h posttransfection, cells were collected and assayed for luciferase and alkaline phosphatase activities. All experiments were repeated at least three times.

Electrophoretic mobility shift assay. Double-stranded oligonucleotides (5’-TAAGTGTGAAGCGATATCCTCAACTCTTAACAG-3’ and 5’-CTGTTAAGAGTTGAGGATATCGCTTCACACTTG-3’) were end labeled with [γ-32P]ATP by using T4 polynucleotide kinase according to standard procedures. Nuclear extracts were prepared as previously described (14), and protein concentration was determined with the bicinchoninic acid assay kit (Bio-Rad). Five micrograms of extract was incubated with 100,000 cpm of labeled probe for 20 min at room temperature in 20 μl of buffer containing 10 mM Tris (pH 7.5), 50 mM NaCl, 1 mM dithiothreitol, 1 mM EDTA, 5% glycerol, 0.3 μg bovine serum albumin (BSA), and 2 μg of poly(dI-dC). DNA-protein complexes were analyzed by electrophoresis in a 5% nondenaturing polyacrylamide gel with 0.5% Tris-borate-EDTA buffer. The gel was then dried and exposed at −80°C for autoradiography.

Chromatin immunoprecipitation (ChiP) assays. ChiP assays were performed essentially as previously described (13). Briefly, 3 × 10⁶ HepG2 cells were cross-linked for 30 min at 4°C by adding 1% formaldehyde-containing solution. Cross-linking was stopped by adding glycine to a final concentration of 125 mM for 5 min. Cells were then rinsed with phosphate-buffered saline (PBS), harvested, and centrifuged at 600 × g for 5 min at 4°C. Pellets were resuspended in lysis buffer (50 mM HEPES-KOH at pH 8.0, 1 mM EDTA, 0.5 mM EGTA, 140 mM NaCl, 10% glycerol, 0.5% NP-40, 0.25% Triton, 1 mM phenylmethylsulfonyl fluoride [PMSF], leupeptin- pepstatin A- apropin at 5 μg/ml each) and rotated for 1 h at 4°C. The nuclei were collected by centrifugation, resuspended in 10 ml wash buffer (10 mM Tris-HCl at pH 8.1, 1 mM EDTA, 0.5 mM EGTA, 200 mM NaCl, 1 mM PMSF, leupeptin- pepstatin A- apropin at 5 μg/ml each), and rotated again. Washed nuclei were centrifuged and resuspended in 1× radioimmunnoprecipitation assay buffer (10 mM Tris-HCl at pH 8.1, 1 mM EDTA, 0.5 mM EGTA, 140 mM NaCl, 1% Triton, 0.1% sodium deoxycholate, 1% Triton X-100) and incubated at 4°C for 1 h with 2 μg of an LRH-1 antibody (from Santa Cruz Biotechnology) and an IgG control antibody (from Santa Cruz Biotechnology). The nuclear suspension was immunoprecipitated as described by ChIP assays.

FIG. 1. LRH-1 overexpression in human hepatic cells. (A) Western blot analysis of LRH-1 in HepG2 cells infected with Ad-LRH-1 or Ad-GFP (MOI = 10). (B to D) HepG2 cells cultured in 24-well plates were infected for 24 h with Ad-LRH-1 or Ad-GFP at various MOIs (1, 5, 10). At the end of the treatment period, total RNA was extracted and gene expression levels were monitored by RT-QPCR.
0.1% Na-deoxycholate, 1 mM PMSF, leupeptin-pepstatin A-aprotinin at 5 μ/ml each) and subsequently sonicated, leading to the generation of DNA fragment sizes of 0.3 to 1.5 kb. Samples were cleared by centrifugation at 16,000 g for 10 min at 4°C. Ten percent of the cleared supernatant was used as the input, and the remaining volume was immunoprecipitated with a C/EBP monoclonal antibody (sc-7962 at 5 μ/ml; Santa Cruz). After extensive washings, proteins were digested by adding proteinase K (100 μ/ml) and placed at 55°C for 3 h, followed by 6 h at 65°C to reverse cross-links. DNA was extracted by a standard procedure, and pellets were resuspended in Tris-EDTA buffer. The human proximal HP promoter region was PCR amplified with the oligonucleotides HPCHIP_F (5'-GCCTGGGCAACAGGAGTGAAA-3') and HPCHIP_R (5'-CTTGGTTGGTCTTGCCTCTGG-3'). PCRs were analyzed by electrophoresis on a 1% agarose gel.

**Experimental protocols** Experimental protocols were approved by the GlaxoSmithKline Institutional Animal Care and Use Committee. Female wild-type and LRH-1+/− mice (25) (eight per group) received an intraperitoneal injection of a lipopolysaccharide (LPS) solution (40 μg per mouse) or saline. At 2.5 h postinjection, animals were sacrificed, blood was recovered for serum preparation, and the liver was quickly removed, frozen in liquid nitrogen, and used for RNA extraction. Acute-phase protein levels in plasma were measured by enzyme-linked immunosorbent assays (ELISAs) (CRP, Kamiya; HP, ICL; SAA, Phase).

**FIG. 2.** Ectopic expression of LRH-1 inhibits the inflammatory response elicited by IL-1β and IL-6 in hepatic cells. HepG2 cells (A to C) and primary cynomolgus hepatocytes (D to F) cultured in 24-well plates were infected for 24 h with Ad-LRH-1 (black bars) or Ad-GFP (white bars) at an MOI of 10 or 50, respectively. Cells were then stimulated with IL-1β (10 ng/ml), IL-6 (10 ng/ml), or the vehicle (PBS-0.1% BSA) for 6 h. At the end of the treatment period, total RNA was extracted and gene expression levels were monitored by RT-QPCR. LRH-1 overexpression resulted in 10- and 20-fold induction of LRH-1 expression in HepG2 cells and in primary hepatocytes, respectively.

**FIG. 3.** Ectopic expression of LRH-1 inhibits IL-1β- and IL-6-mediated HP induction in a dose-dependent manner. HepG2 cells (A and B) were infected for 24 h with increasing MOIs of Ad-LRH-1 or Ad-GFP. Cells were then stimulated with IL-1β (10 ng/ml), IL-6 (10 ng/ml), or the vehicle (PBS-0.1% BSA) for 6 h. At the end of the treatment period, HP and LRH-1 mRNA levels were measured by RT-QPCR.
Statistical analysis. Results are shown as means ± the standard errors of the means. Statistical significance was determined with the Student t test. Differences with P < 0.05 were considered to be statistically significant.

RESULTS

In order to investigate a potential involvement of LRH-1 in the control of the hepatic APR, we generated an adenovirus encoding FLAG-tagged human LRH-1 (Ad-LRH-1). Infection of HepG2 cells, a human hepatic cell line, with Ad-LRH-1 led to robust expression of LRH-1 at both the mRNA and protein levels (Fig. 1A and B). Overexpression of the FLAG-tagged LRH-1 protein resulted in dose-dependent induction of APOA1 and SRB1, two previously characterized LRH-1 target genes (13, 48), thereby confirming the functionality of the LRH-1 protein produced (Fig. 1C and D). Next, HepG2 cells were infected with Ad-LRH-1 or Ad-GFP for 24 h. Cells were subsequently stimulated for 6 h with IL-1β or IL-6, two key mediators of the APR (3). Type 1 and type 2 APR gene expression levels were monitored by RT-QPCR (Fig. 2A to D).

Ectopic expression of LRH-1 in HepG2 cells did not significantly affect basal SAA, HP, or FGB gene expression levels. As expected, IL-1β and IL-6 treatment resulted in significant induction of HP, SAA, and FGB gene expression, which was blunted by LRH-1 overexpression (Fig. 2A to C). Similar results were obtained with primary cynomolgus hepatocytes (Fig. 2D to F). In addition, LRH-1 prevented cytokine-mediated CRP gene induction in primary hepatocytes (data not shown).

FIG. 4. Ectopic expression of LRH-1 inhibits IL-1β- and IL-6-mediated HP secretion in HepG2 cells. (Top) Western blot analysis of HP secretion in HepG2 cells infected with Ad-LRH-1 (MOI = 10) or Ad-GFP stimulated with IL-1β, IL-6, or the vehicle (PBS–0.1% BSA) for 6 h. (Middle) Intracellular LRH-1 detection by Western blot assay in HepG2 cells infected with Ad-LRH-1 (MOI = 10) or Ad-GFP stimulated with IL-1β, IL-6, or the vehicle (PBS–0.1% BSA) for 6 h. (Bottom) Nonspecific (NS) band used as a loading control.

Furthermore, LRH-1 inhibited cytokine-mediated HP secretion into the medium by Western blot analysis (Fig. 3A). This inhibition also occurs at the protein level, as demonstrated by analysis of HP secretion into the medium by Western blot analysis (Fig. 3A). Of note, treatment with IL-1β and IL-6 did not affect LRH-1 mRNA expression in HepG2 cells (Fig. 3B). Taken together, these results suggest that LRH-1 negatively regulates the hepatic inflammatory response elicited by IL-1β or IL-6 in vitro.

To further explore the anti-inflammatory properties of LRH-1, gene-silencing experiments were carried out with HepG2 cells. To knock down LRH-1 expression, HepG2 cells stably expressing shRNA targeting LRH-1 or LacZ expression. In those cells, LRH-1 mRNA expression was dramatically reduced (~80%) compared to

FIG. 5. shRNA-mediated LRH-1 knockdown in HepG2 cells results in an exacerbated inflammatory response. (A) LRH-1, APO AI, and SHP mRNA levels were determined by RT-QPCR in HepG2 cells stably transduced with a vector expressing shRNA targeting LRH-1 or LacZ expression. (B to D) shLRH-1 or shLacZ HepG2 cells were stimulated by IL-1β (10 ng/ml), IL-6 (10 ng/ml), or the vehicle (PBS–0.1% BSA) for 6 h. At the end of the treatment period, HP, SAA, and FGB gene expression levels were measured by RT-QPCR. *, P < 0.05 (shLacZ versus shLRH-1).
shLacZ-expressing HepG2 cells, as demonstrated by RT-QPCR (Fig. 5A). In addition, LRH-1 knockdown led to transcriptional inhibition of the expression of both SHP and APOAI (Fig. 5A), two well-established LRH-1 target genes, in hepatic cells (13, 24). Stimulation for 6 h with IL-1β or IL-6 resulted in induction of the genes for HP, SAA, and FGB in control cells (Fig. 5B to D), in line with our previous results (Fig. 2). Interestingly, this inflammatory response was significantly more pronounced in shLRH-1-expressing cells, indicating that LRH-1 negatively regulates the transcriptional response elicited by both IL-1β and IL-6 in hepatic cells (Fig. 5B to D).

A large number of studies have led to the identification of several signaling pathways controlling the transcription of the APR genes, including those for NF-κB, STAT3, and C/EBP (13, 19, 24, 42, 44). To gain some insight into the molecular mechanism by which LRH-1 exerts these anti-inflammatory properties, the influence of LRH-1 overexpression was tested on minimal promoters driven by multiple copies of NF-κB, STAT3, and C/EBP binding sites (Fig. 6A to C). As expected, IL-1β treatment led to the transcriptional activation of NF-κB, C/EBP, and to a lesser extent STAT3 promoter vectors. By contrast, IL-6 stimulation induced both STAT3 and C/EBP but not NF-κB promoter activation (Fig. 6A to C). Cotransfection of LRH-1 did not affect the basal promoter activity of those reporter vectors, while it completely blocked IL-1β-mediated but also IL-6-mediated C/EBP transcriptional activation (Fig. 6C). By contrast, LRH-1 failed to negatively interfere with the transcriptional activation of both STAT3 and NF-κB (Fig. 6A and B). These results indicate that LRH-1 antagonizes cytokine-induced C/EBP but not STAT3 or NF-κB transcriptional activation. Interestingly, the SAA, HP, and FGB promoters have been shown to contain functional C/EBP binding motifs (4, 19, 38, 46). To further characterize the transcriptional cross talk between LRH-1 and the C/EBP signaling pathway, a 0.45-kb promoter fragment of the human HP gene was cloned upstream of the luciferase reporter gene. Cotransfection of increasing amounts of an LRH-1-expressing vector did not significantly affect the basal human HP promoter activity (Fig. 6D). As expected, treatment with both IL-6 and IL-1β resulted in strong induction of reporter activity (six- and threefold, respectively). This promoter induction was inhibited by LRH-1 cotransfection in a dose-dependent manner (Fig. 6D). To determine whether LRH-1 inhibits cytokine-induced HP promoter activity by antagonizing C/EBP signaling, a promoter construct bearing a mutation for the C/EBP

FIG. 6. LRH-1 negatively regulates HP gene expression at the transcriptional level, at least in part, by antagonizing the C/EBP signaling pathway. HepG2 cells were transfected with the NF-κB (A), STAT3 (B), or C/EBP (C) reporter construct and pSG5-LRH-1 (200 ng) or the empty vector (pSG5). At 24 h posttransfection, cells were stimulated with IL-6 (10 ng/ml), IL-1β (10 ng/ml), or the vehicle (PBS–0.1% BSA) for 6 h. Luciferase activity was then determined. HepG2 cells were transfected with the wild-type human HP promoter (D) or a construct mutated for the C/EBP binding site (E) and increasing concentrations of pSG5-LRH-1 (0, 50, 100, and 200 ng) or the empty vector (pSG5). At 24 h posttransfection, cells were stimulated with IL-6 (10 ng/ml), IL-1β (10 ng/ml), or the vehicle (PBS–0.1% BSA) for 6 h. Luciferase activity was then determined.
binding site located in the proximal promoter was generated by site-directed mutagenesis. This mutated construct displayed a significantly lower basal activity (~75%) compared to the wild-type promoter (Fig. 6E), in agreement with published reports (4). Interestingly, this promoter construct was still responsive to both IL-1β and IL-6, but to a lesser extent compared to the wild-type construct. Cotransfection of increasing amounts of LRH-1 failed to inhibit this cytokine-induced promoter activity, suggesting that LRH-1 inhibits HP promoter activation by negatively interfering with the C/EBP signaling pathway (Fig. 6E). As a control, LRH-1 cotransfection did not modify the basal activity of the mutated promoter (Fig. 6B). Taken together, these results suggest that LRH-1 antagonizes C/EBP transcriptional activation, leading to HP promoter inhibition.

To study the molecular basis of the transcriptional cross talk between LRH-1 and C/EBP signaling, electrophoretic mobility shift assays were performed with nuclear extracts from HepG2 cells. Supershift experiments demonstrated that C/EBPβ was the main C/EBP isoform binding to the HP promoter, in agreement with other reports (45) (Fig. 7A). Ad-GFP-infected HepG2 cells, in the absence of cytokine treatment, display a weak C/EBP DNA-binding activity which was not affected by LRH-1 ectopic expression (Fig. 7B). As expected, IL-1β and IL-6 treatment resulted in an increase in C/EBP DNA-binding capacity in ad-GFP-infected cells, which is consistent with the higher transcriptional activity (Fig. 6C). LRH-1 overexpression sharply reduced this DNA-binding activity. Importantly, nuclear C/EBPβ levels (and HNF4α as a loading control) were not modified by LRH-1 overexpression or by cytokine treatments (Fig. 7C). In order to demonstrate that LRH-1 inhibits cytokine-induced C/EBPβ DNA binding in vivo, ChIP assays were performed. The IL-1β–IL-6 combination induced a significant increase in C/EBPβ occupancy on the HP promoter. This increase was completely abrogated by LRH-1 overexpression, in line with our previous electrophoretic mobility shift assay results (Fig. 7B). Interestingly, under resting conditions, C/EBPβ recruitment to the HP proximal promoter was not affected by LRH-1 ectopic expression. Taken together, these results suggest that LRH-1 negatively interferes with the C/EBP pathway by, at least in part, preventing its DNA binding.

Finally, to further examine the biological relevance of LRH-1 anti-inflammatory properties in vivo, we studied the response to an LPS challenge in wild-type and LRH-1 heterozygous mice. Female mice (eight per group) received an intraperitoneal injection of an LPS solution (40 μg per animal) or saline. At 2.5 h postinjection, animals were sacrificed and the APR was studied at the protein and gene expression levels (Fig. 8). LPS treatment resulted in strong induction of acute-phase gene expression, as measured by RT-QPCR (Fig. 8A to C). This inflammatory response was much more pronounced in LRH-1 heterozygous mice (Fig. 8A to C). Quantification of plasma APP levels by ELISA confirmed the gene expression data, i.e., an exacerbated inflammatory response in LRH-1+/− mice (Fig. 8D to F). Interestingly, basal CRP and gene expression levels were higher in LRH-1 heterozygous than in wild-type mice. As a control, hepatic LRH-1 expression was monitored by RT-QPCR.
QPCR. In wild-type and LRH-1−/− mice, LRH-1 expression was not modified by LPS challenge (data not shown). Collectively, these results demonstrate that LRH-1 is a negative regulator of the hepatic APR in vitro and in vivo.

**DISCUSSION**

LRH-1 has been shown to be an important regulator of cholesterol homeostasis (15) and to be involved in intestinal crypt cell renewal (6). In the present study, we investigated the functional implication of this orphan NR in the control of the hepatic APR. LRH-1 overexpression resulted in inhibition of IL-1- and IL-6-mediated FBG, SAA, CRP, and HP gene expression in hepatocytes. It has also been shown that partial LRH-1 deficiency leads to an exacerbated inflammatory response in vitro and in vivo (Fig. 5 and 8), indicating that LRH-1 is a physiological modulator of the hepatic APR. Several members of the NR superfamily have been shown to play a role in the control of the inflammatory response (23). For instance, LXR and PPARγ have been shown to be molecular links between lipid metabolism and inflammation by negatively interfering with several transcription factors, such as C/EBPs, AP-1, and NF-κB (10, 27, 29, 35). In this study, we identified a set of APR genes down-regulated by LRH-1 in hepatic cells. Interestingly, all of those genes contain functional C/EBP binding sites within their promoter regions and we show that LRH-1 was capable of blocking the C/EBP-dependent activation of an isolated C/EBP response element, suggesting that LRH-1 blocks C/EBP signaling. This phenomenon seemed to be specific for C/EBP since transient-transfection experiments revealed that LRH-1 was unable to antagonize cytokine-stimulated NF-κB- and STAT3-driven transcription (Fig. 6A and B), in contrast to other NRs, such as LXR and PPARγ (27). These results suggest that LRH-1 likely inhibits a distinct pattern of inflammatory gene expression compared to LXR, for instance. This is consistent with the concept that every NR may differentially impact the development of the inflammatory response (23). Further studies requiring microarray analysis should help us to better understand the role of LRH-1 during the APR. Interestingly, Schoonjans and coworkers reported an inverse correlation between LRH-1 and tumor necrosis factor alpha (TNF-α) gene ex-
pression in the colon (49). In their study, C57BL6 mice received an intraperitoneal injection of LPS (100 μg/mouse). LRH-1 and TNF-α mRNA levels were quantified in colon biopsies at 6 or 24 h postinjection. This high dose of LPS resulted in a significant reduction of LRH-1 expression (−50%) after 24 h with a parallel induction of TNF-α. Furthermore, LRH-1 haploinsufficiency resulted in modulation of the inflammatory response in the intestine (49), in line with the results reported here.

The C/EBPs belong to a family of leucine zipper transcription factors involved in the control of inflammatory and native immunity functions (42). All of the genes inhibited by LRH-1 in response to cytokine stimulation contain functional C/EBP DNA-binding sites within their promoter regions. Site-directed mutagenesis and transfection experiments revealed that LRH-1 negatively regulates APR gene expression by antagonizing the C/EBP signaling pathway. Interestingly, the C/EBP-mutated reporter construct was responsive to treatment with both IL-1β and IL-6, but to a lesser extent compared to the wild-type promoter. However, LRH-1 cotransfection failed to inhibit this transcriptional activation, suggesting that LRH-1 does not interfere with other transcription factors, such as STAT3, involved in HP promoter regulation (43). LRH-1 inhibits C/EBP transcriptional activity by, at least in part, reducing C/EBP DNA binding in vitro and in vivo, as demonstrated by electrophoretic mobility shift and ChIP assays (Fig. 7). Supershift experiments suggest that C/EBPβ is the main C/EBP involved in this transcriptional cross talk; however, LRH-1 overexpression did not affect total or nuclear C/EBPβ levels (Fig. 7).

Preliminary coimmunoprecipitation experiments failed to demonstrate a direct protein-protein interaction between LRH-1 and C/EBPβ in hepatic cells (data not shown). Interestingly, C/EBPβ is known to undergo a number of posttranslational modifications, such as phosphorylation and SUMOylation, that modulate its transcriptional activity (50). For instance, C/EBPβ phosphorylation by protein kinase C enhances its transcriptional activity (51). More recently, Kim and coworkers identified a conserved inhibitory domain within C/EBP that is a target for SUMOylation (28). Attachment of SUMO-1 to a lysine residue identified in this region decreases the transcriptional inhibitory function of this domain (28).

Interestingly, Pascual and colleagues recently reported a SUMOylation-dependent pathway involved in PPARγ-mediated transrepression of the inflammatory response genes (41).

Whether or not this mechanism is also operative for other NRs implicated in transcriptional cross talk has not been determined. Similarly to PPARγ, LRH-1 has been shown to be SUMOylated (9, 31). Further studies are required to determine whether LRH-1 antagonizes C/EBPβ transcriptional activity via a SUMOylation-dependent pathway.

LRH-1 was originally identified as a key player in cholesterol homeostasis (15). LRH-1 is involved in the control of bile acid biosynthesis via regulation of the expression of the genes for both CYP7A1 and CY8B1 (7, 37). Moreover, LRH-1 has also been reported to regulate the expression of APOAI (13), CETP (33), and SR-BI (48), thereby implicating this receptor in HDL remodeling and cholesterol transport. HDL per se is known to have anti-inflammatory properties (2). For instance, HDL is known to modulate LDL-induced monocyte chemotactic activity in the human artery wall (36). Furthermore, HDL plays an important role as an antioxidant by inhibiting phospholipid oxidation and by decreasing the activity of minimally modified LDL (55). However, during the APR or another chronic systemic inflammatory response, HDL can assume proinflammatory and proatherogenic characteristics (17, 52). HDL isolated from patients with coronary artery disease increased LDL-induced recruitment of monocytes to endothelial and smooth-muscle cells (1). SAA, an APP that is dramatically induced in plasma during the APR, is able to displace APOAI from HDL in vitro (52). In addition, because SAA binds to proteoglycans, SAA-containing HDL may be retained by the vascular matrix, leading to the formation of proatherogenic particles that do not participate in reverse cholesterol transport anymore. By negatively regulating the expression of APP that are well-established markers of coronary artery disease and by controlling HDL biosynthesis and remodeling, LRH-1 may quantitatively affect and qualitatively modulate HDL levels, ultimately resulting in a slowdown of the development of atherosclerosis. Further studies using transgenic animals should help to address this question.

In conclusion, our results outline an unexpected role for LRH-1 in the control of the hepatic APR and suggest that LRH-1 could be a novel molecular link between cholesterol homeostasis and inflammation. On the basis of these observations, LRH-1 appears to be an interesting target for the treatment of dyslipidemia and atherosclerosis.

ACKNOWLEDGMENTS

We thank John Bisi (GSK, gene interference) for providing FLAG-tagged Ad-LRH-1, Stéphane Huet (GSK, CVU CEDD) for critical reading of the manuscript, and Beverly H. Koller and Anne M. Latour (Department of Medicine, University of Chapel Hill, Chapel Hill, NC) for LRH-1 heterozygous mice.

REFERENCES


29. Ranjii, D. P., A. Vitelli, F. Tronche, R. Cortese, and G. Ciliberto. 1993. The two C/EBP isoforms, IL-6DBP/NF-IL6 and C/EBP/NEf1, are induced by IL-6 to promote acute phase gene transcription via different mechanisms. EMBO J. 12:2195–2202.


